BR112021022646A2 - Processos e intermediários para a preparação de um inibidor de btk - Google Patents

Processos e intermediários para a preparação de um inibidor de btk

Info

Publication number
BR112021022646A2
BR112021022646A2 BR112021022646A BR112021022646A BR112021022646A2 BR 112021022646 A2 BR112021022646 A2 BR 112021022646A2 BR 112021022646 A BR112021022646 A BR 112021022646A BR 112021022646 A BR112021022646 A BR 112021022646A BR 112021022646 A2 BR112021022646 A2 BR 112021022646A2
Authority
BR
Brazil
Prior art keywords
preparation
processes
intermediates
btk inhibitor
ibrutinib
Prior art date
Application number
BR112021022646A
Other languages
English (en)
Inventor
Andras Horvath
Bernardus Kaptein
Karel Maria Verzijl Gerardus
Jinxiong Su
Laurent Lefort
James Pye Philip
Yuanyuan Yuan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112021022646A2 publication Critical patent/BR112021022646A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/02—Preparation by ring-closure or hydrogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98—Nitrogen atom

Abstract

processos e intermediários para a preparação de um inibidor de btk. a presente invenção refere-se a um processo para a preparação de certos intermediários, por exemplo, um processo para a preparação de um composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, em uma forma enriquecida enantiomericamente, cujo intermediário e processos são úteis na preparação de um inibidor de btk, tal como ibrutinibe.
BR112021022646A 2019-05-21 2020-05-20 Processos e intermediários para a preparação de um inibidor de btk BR112021022646A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019087804 2019-05-21
PCT/EP2020/064119 WO2020234379A1 (en) 2019-05-21 2020-05-20 Processes and intermediates for preparing a btk inhibitor

Publications (1)

Publication Number Publication Date
BR112021022646A2 true BR112021022646A2 (pt) 2022-03-29

Family

ID=70857159

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022646A BR112021022646A2 (pt) 2019-05-21 2020-05-20 Processos e intermediários para a preparação de um inibidor de btk

Country Status (11)

Country Link
US (1) US20220235058A1 (pt)
EP (1) EP3972956A1 (pt)
JP (1) JP2022533219A (pt)
KR (1) KR20220011669A (pt)
CN (1) CN113906011A (pt)
AU (1) AU2020280904A1 (pt)
BR (1) BR112021022646A2 (pt)
CA (1) CA3135211A1 (pt)
IL (1) IL288155A (pt)
MX (1) MX2021014245A (pt)
WO (1) WO2020234379A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
SI2414363T1 (sl) 2009-03-31 2014-04-30 Boehringer Ingelheim Gmbh Derivati 1-heterociklil-1,5-dihidro-pirazolo/3,4-d/pirimidin-4-ona in njihova uporaba kot modulatorji za PDE9A
US20150291554A1 (en) * 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
MY194905A (en) * 2013-03-15 2022-12-22 Janssen Pharmaceutica Nv Processes and Intermediates for Preparing a Medicament
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN106795124A (zh) * 2014-10-30 2017-05-31 桑多斯股份公司 取代的1H‑吡唑并[3,4‑d]嘧啶类化合物的合成
MA41350A (fr) * 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
CN107233344B (zh) * 2017-07-20 2021-03-02 河南师范大学 一种抗肿瘤药物依鲁替尼的制备方法
CN107385966A (zh) * 2017-07-20 2017-11-24 毛龙飞 一种新型有机硅类皮革染色助剂及其制备方法
CN107383017B (zh) * 2017-07-20 2020-01-14 河南师范大学 依鲁替尼高效制备方法
CN109180683A (zh) * 2018-09-07 2019-01-11 南通雅本化学有限公司 一种依鲁替尼的制备方法

Also Published As

Publication number Publication date
JP2022533219A (ja) 2022-07-21
AU2020280904A1 (en) 2021-11-18
WO2020234379A1 (en) 2020-11-26
MX2021014245A (es) 2022-01-06
KR20220011669A (ko) 2022-01-28
EP3972956A1 (en) 2022-03-30
IL288155A (en) 2022-01-01
CN113906011A (zh) 2022-01-07
US20220235058A1 (en) 2022-07-28
CA3135211A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
AR111495A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
BR112018075433A2 (pt) derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os
BR112017027831A2 (pt) derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os
BR112017023740A2 (pt) ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida?
BR112014004219A2 (pt) pirano[3,2-d][1,3]tiazol como inibidores de glicosidase
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112017017349A2 (pt) composto, composição, método para tratar um distúrbio
BR112014010401A8 (pt) Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
BR112014006559A2 (pt) derivados do ácido betulínico com atividade antiviral
BR112018073488A2 (pt) intermediários para a síntese de derivados de ácido biliar, em particular de ácido obeticólico
BR112018074027A2 (pt) tiofeno, método de fabricação do mesmo, e aplicação farmacêutica do mesmo
BR112014018636A8 (pt) Derivados de benzil sulfonamida úteis como inibidores de mogat-2
CO6321288A2 (es) Sales de compuestos inhibidores de vih
BR112017001847A2 (pt) processo para a preparação de um composto de fórmula (i), mistura, composição e composto de fórmula (ii)
CO2018007008A2 (es) "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"
AR086987A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase
CU20120065A7 (es) Derivado de 4-[etil(dimetil)amonio] butanoato para el tratamiento de enfermedades cardiovasculares y sus métodos de obtención
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
BR112015015229A8 (pt) processo para a preparação de um composto da fórmula, e, composto
BR112022009493A2 (pt) Fabricação de do3a protegido
BR112014009760A8 (pt) análogos de ácido siálico
BR112012019866A2 (pt) composto, composição farmacêutica, método de tratamento das infecções virais, e, processo para preparar um composto